Free Trial

Anpario's (ANP) "House Stock" Rating Reaffirmed at Shore Capital

Anpario logo with Consumer Defensive background

Key Points

  • Anpario's stock rating was reaffirmed as a "house stock" by analysts at Shore Capital, indicating a stable confidence in the company's performance.
  • The company reported a net margin of 9.23% and an estimated EPS of 23.58 for the current fiscal year, highlighting its profitability prospects.
  • As of Tuesday, Anpario's shares traded at GBX 485.20, within a 52-week range of GBX 286 to GBX 510.
  • Five stocks we like better than Anpario.

Anpario (LON:ANP - Get Free Report)'s stock had its "house stock" rating reaffirmed by stock analysts at Shore Capital in a research note issued on Tuesday,Digital Look reports.

Anpario Trading Down 0.5%

Shares of ANP stock opened at GBX 485.20 on Tuesday. The company has a market capitalization of £82.22 million, a price-to-earnings ratio of 1,986.90 and a beta of 0.58. The company has a debt-to-equity ratio of 0.10, a quick ratio of 5.16 and a current ratio of 6.15. Anpario has a 52-week low of GBX 286 and a 52-week high of GBX 510. The company has a 50-day simple moving average of GBX 415.85 and a two-hundred day simple moving average of GBX 414.64.

Anpario (LON:ANP - Get Free Report) last released its quarterly earnings data on Wednesday, September 10th. The company reported GBX 16.87 EPS for the quarter. Anpario had a net margin of 9.23% and a return on equity of 8.74%. Research analysts anticipate that Anpario will post 23.5757801 EPS for the current fiscal year.

Anpario Company Profile

(Get Free Report)

Anpario plc, together with its subsidiaries, engages in the production and distribution of natural feed additives for animal health, hygiene, and nutrition. Its health and performance category offers various products that support and maintain animal gut health, such as phytogenic and acid based eubiotics, and omega fatty acids under the Orego-Stim, Optomega, pHorce, Salkil, and Genex brands; feed quality category provides products, such as enzymes, antioxidants, pellet binders, mould inhibitors, and acid based eubiotics under the pHorce, Feedzyme, Salgard, Oxigard, Moldgard, and Mastercube brands.

Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Anpario Right Now?

Before you consider Anpario, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Anpario wasn't on the list.

While Anpario currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report
Like this article? Share it with a colleague.